{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70781"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/hgh-fragment-176-191\/","title":{"rendered":"Fragmento de HGH 176-191"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o Fragmento HGH 176-191?<\/h3>\n<p style=\"margin: 0;\"><strong>Fragmento de HGH 176-191<\/strong> \u00e9 um p\u00e9ptido sint\u00e9tico de 16 amino\u00e1cidos correspondente aos res\u00edduos C-terminais 176\u2013191 da <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">hormona de crescimento humana<\/a>. In published studies it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">66004-57-7 (Fragmento HGH 176-191; distinto do AOD9604 CAS 221231-10-9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1817.06 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF, 16 amino\u00e1cidos; posi\u00e7\u00f5es 176\u2013191 da hormona de crescimento humana nativa, retendo a ponte dissulfeto Cys182\u2013Cys189 da mol\u00e9cula parental)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco sujo)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para per\u00edodos de utiliza\u00e7\u00e3o mais curtos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 o Fragmento HGH 176-191?<\/h2>\n<p><strong>Fragmento de HGH 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function studies on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule. The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C<sub>78<\/sub>H<sub>125<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. O Fragmento HGH 176-191 \u00e9 estrutural e farmacologicamente <strong>distinto do AOD9604<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here. HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the full-length parent molecule, see our <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> p\u00e1gina de produto. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Atividade Lipol\u00edtica Sem Liga\u00e7\u00e3o ao Receptor de GH<\/h2>\n<p>O que torna o fragmento HGH 176-191 mecanicamente distinto \u00e9 a <strong>dissocia\u00e7\u00e3o da lip\u00f3lise da sinaliza\u00e7\u00e3o do eixo de crescimento<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology studies:<\/p>\n<ul>\n<li><strong>Aus\u00eancia de liga\u00e7\u00e3o ao receptor de GH<\/strong> \u2014 A superf\u00edcie de liga\u00e7\u00e3o ao receptor de GH da HGH nativa est\u00e1 contida na por\u00e7\u00e3o N-terminal da mol\u00e9cula (regi\u00e3o dos res\u00edduos 1\u2013120), n\u00e3o no fragmento C-terminal 176\u2013191. Como resultado, o fragmento HGH 176-191 N\u00c3O se liga ao receptor da hormona de crescimento (GHR), N\u00c3O ativa a sinaliza\u00e7\u00e3o JAK2\/STAT5, N\u00c3O induz a produ\u00e7\u00e3o hep\u00e1tica de IGF-1 e N\u00c3O produz qualquer um dos efeitos promotores de crescimento, estimulantes de condr\u00f3citos ou contra-reguladores de insulina da mol\u00e9cula <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> molecule. This is the defining negative pharmacological property and the basis for its studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>Atividade lipol\u00edtica preservada<\/strong> \u2014 Published studies has documented that HGH Fragment 176-191 retains the fat-mobilising activity of full HGH at adipocytes. The exact molecular target underlying the lipolytic effect remains an active studies question; proposed mechanisms include direct action on adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase, and altered fatty-acid oxidation kinetics. The lipolytic signal is preferentially observed in visceral adipose tissue depots in some published rodent studies, paralleling but mechanistically distinct from the <a href=\"https:\/\/medsbase.com\/pt-pt\/tesamorelin\/\">Tesamorelin<\/a> visceral-adiposity signal.<\/li>\n<li><strong>Atividade antilipog\u00e9nica<\/strong> \u2014 In addition to stimulating fat mobilisation, HGH Fragment 176-191 suppresses lipogenic gene expression in adipocyte study models \u2014 reducing the rate of new fat storage in parallel with increasing fat mobilisation. The two effects produce a net negative-fat-balance signal in adipose tissue.<\/li>\n<\/ul>\n<p>The structure-function-decoupling property is the principal scientific reason HGH Fragment 176-191 has remained in active studies despite never reaching regulatory approval as a stand-alone therapeutic. It is a useful tool for users who want to study HGH&#8217;s lipolytic effects independently from its growth-promoting effects \u2014 a separation that is impossible to achieve with full-length HGH or with GH secretagogues that drive endogenous full-length GH release. Plasma half-life is short (~30 minutes); subcutaneous administration is the standard administration route. <\/p>\n<h2>Published Evidence<\/h2>\n<p>HGH Fragment 176-191 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia da lip\u00f3lise em adip\u00f3citos<\/strong> \u2014 caracteriza\u00e7\u00e3o do mecanismo lipol\u00edtico isolado, estudos de intera\u00e7\u00e3o com recetores adren\u00e9rgicos beta-3, ativa\u00e7\u00e3o da lipase sens\u00edvel a hormonas, cin\u00e9tica de mobiliza\u00e7\u00e3o de \u00e1cidos gordos<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), regional adipose-tissue depot effects (visceral vs subcutaneous), lipolysis-without-growth-axis-confound studies designs<\/li>\n<li><strong>HGH structure-function studies<\/strong> \u2014 dissec\u00e7\u00e3o mecanicista dos dom\u00ednios de atividade promotora de crescimento vs lipol\u00edtica na HGH nativa; Fragmento 176-191 da HGH como a ferramenta can\u00f3nica \u201capenas lip\u00f3lise\u201d, com <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> como comparador de atividade total<\/li>\n<li><strong>Lipogenic gene-expression studies<\/strong> \u2014 diferencia\u00e7\u00e3o de adip\u00f3citos, forma\u00e7\u00e3o de got\u00edculas lip\u00eddicas, intera\u00e7\u00f5es com as vias PPAR\u03b3 e SREBP-1<\/li>\n<li><strong>Visceral adiposity studies<\/strong> \u2014 compara\u00e7\u00f5es diretas com <a href=\"https:\/\/medsbase.com\/pt-pt\/tesamorelin\/\">Tesamorelin<\/a> as the GHRH-axis visceral-fat-reducing tool; published interest in dissecting GH-receptor-dependent vs GH-receptor-independent visceral-fat-loss mechanisms<\/li>\n<li><strong>Glucose homeostasis studies<\/strong> \u2014 unlike full-length HGH, HGH Fragment 176-191 does not produce the insulin-counter-regulatory effects observed with parent HGH; published studies uses this difference to dissect direct GH glycaemic effects<\/li>\n<li><strong>Comparative HGH-axis studies<\/strong> \u2014 compara\u00e7\u00e3o com <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> (forma parental completa), <a href=\"https:\/\/medsbase.com\/pt-pt\/tesamorelin\/\">Tesamorelin<\/a> (an\u00e1logo de GHRH para gordura visceral), e <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> \/ <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295<\/a> (estimuladores do eixo GHRH).<\/li>\n<\/ul>\n<p>For broader context on where HGH Fragment 176-191 fits within the growth-axis and adipose-tissue studies landscape, see <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> como o pept\u00eddeo parental completo, <a href=\"https:\/\/medsbase.com\/pt-pt\/tesamorelin\/\">Tesamorelin<\/a> para a abordagem do eixo GHRH \u00e0 adiposidade visceral, e <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> + <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for endogenous GH-pulse support. Browse the full <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks HGH Fragment 176-191 in three lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-cohort lipolysis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week protocols<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo prolongado, menor custo por mg, estudos com m\u00faltiplas coortes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>Como Comparar \u2014 Fragmento de HGH 176-191 vs HGH 191AA<\/h2>\n<p>Fragmento de HGH 176-191 e <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> are a structure-function decoupled pair \u2014 the fragment is literally a piece of the full-length parent. Comparing them isolates the GH-receptor-binding activity (present in full-length, absent in fragment) from the lipolytic activity (present in both). The comparison is one of the cleanest mechanistic dissections available in current growth-axis studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Fragmento de HGH 176-191<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH 191AA (mol\u00e9cula completa)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">16 amino\u00e1cidos (~1,8 kDa)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">191 amino\u00e1cidos (~22 kDa)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Liga\u00e7\u00e3o ao receptor de GH<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00e3o (o dom\u00ednio de liga\u00e7\u00e3o \u00e9 N-terminal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sim (mol\u00e9cula completa)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Indu\u00e7\u00e3o de IGF-1<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indu\u00e7\u00e3o hep\u00e1tica substancial<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Atividade lipol\u00edtica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sim (preservada)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sim (atividade parental de comprimento total)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeitos promotores de crescimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Substancial (p\u00e9ptido anab\u00f3lico can\u00f3nico)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito contra-regulador da insulina<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00e3o<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sim (resist\u00eancia \u00e0 insulina transit\u00f3ria)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~30 minutos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~3\u20135 horas<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Uso cl\u00ednico aprovado<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Nenhum<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00faltiplas indica\u00e7\u00f5es (Genotropin, Humatrope, etc.)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">200\u2013500 mcg, 1\u20133x por dia<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1\u20138 UI por administra\u00e7\u00e3o<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies interested in isolated lipolysis pharmacology without the confound of GH-receptor-driven growth and metabolic effects, HGH Fragment 176-191 is the canonical &#8220;lipolysis-only&#8221; tool. For studies investigating the full GH\/IGF axis or comparing with secretagogue-driven endogenous GH release, <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> is the appropriate full-length reference. Many published studies designs use both in parallel arms to dissect which HGH effects depend on GH-receptor signalling vs which arise from the C-terminal lipolytic mechanism. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138\u00a0\u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220\u00a0\u00b0C. O Fragmento 176-191 de HGH liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220\u00a0\u00b0C por at\u00e9 36 meses. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. Como outros pept\u00eddeos com pontes dissulfeto, a atividade do fragmento depende da liga\u00e7\u00e3o intacta Cys182\u2013Cys189 (numera\u00e7\u00e3o do fragmento Cys7\u2013Cys14) \u2014 o manuseio que interrompe o dissulfeto degradar\u00e1 a atividade. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco de pept\u00eddeo (n\u00e3o diretamente sobre o bolo liofilizado). Para um frasco de 5\u00a0mg, 2,0\u00a0mL de \u00e1gua bacteriost\u00e1tica produzem uma concentra\u00e7\u00e3o de trabalho de 2,5\u00a0mg\/mL \u2014 0,04\u00a0mL fornece 100\u00a0mcg; 0,1\u00a0mL fornece 250\u00a0mcg; 0,2\u00a0mL fornece 500\u00a0mcg. Agite suavemente \u2014 n\u00e3o <strong>n\u00e3o<\/strong> agite vigorosamente \u2014 e aguarde 2\u20135 minutos para dissolu\u00e7\u00e3o completa. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser l\u00edmpida e incolor. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138\u00a0\u00b0C e use dentro de 30 dias para estabilidade ideal. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do pept\u00eddeo e podem interromper a liga\u00e7\u00e3o dissulfeto. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is HGH Fragment 176-191 used for in studies?<\/h3>\n<p>HGH Fragment 176-191 is used in studies investigating isolated adipocyte lipolysis pharmacology, obesity and body-composition regulation without growth-axis confound, HGH structure-function dissection, lipogenic gene-expression regulation, regional adipose-tissue depot effects, and comparative GH-axis vs lipolysis-only studies designs. It is the canonical &#8220;lipolysis-only&#8221; peptide derived from native HGH. The pharmaceutical-grade HGH Fragment 176-191 sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Como \u00e9 que o Fragmento 176-191 de HGH difere do HGH 191AA?<\/h3>\n<p>O Fragmento 176-191 de HGH tem apenas 16 amino\u00e1cidos \u2014 a parte C-terminal do HGH de comprimento total de 191 amino\u00e1cidos. O fragmento carece do dom\u00ednio de liga\u00e7\u00e3o ao receptor GH (que reside na por\u00e7\u00e3o N-terminal da mol\u00e9cula parental), pelo que N\u00c3O se liga ao GHR, N\u00c3O induz IGF-1 e N\u00c3O produz qualquer um dos efeitos promotores de crescimento ou contra-reguladores da insulina do HGH completo. Ret\u00e9m apenas a atividade lipol\u00edtica e antilipog\u00e9nica. <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> \u00e9 a mol\u00e9cula parental de comprimento total com atividade lipol\u00edtica E do eixo de crescimento. <\/p>\n<h3>Como \u00e9 que o Fragmento 176-191 de HGH difere do AOD9604?<\/h3>\n<p>S\u00e3o <strong>compostos distintos<\/strong> that are frequently confused. HGH Fragment 176-191 (CAS 66004-57-7) is the unmodified C-terminal fragment of native HGH. AOD9604 (CAS 221231-10-9) is a modified analog developed by Metabolic Pharmaceuticals \u2014 specifically, AOD9604 adds an N-terminal tyrosine substitution producing Tyr-HGH 177-191, with engineered changes to the disulfide bridge for improved stability and oral bioavailability studies. The two have related but distinct pharmacology. This product is the unmodified 176-191 fragment, not AOD9604. <\/p>\n<h3>What is the typical HGH Fragment 176-191 dose?<\/h3>\n<p>Published preclinical protocols typically use 200\u2013500\u00a0mcg per administration, given subcutaneously 1\u20133 times daily for 4\u201312 week cycles. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 0.04\u00a0mL equals 100\u00a0mcg, 0.2\u00a0mL equals 500\u00a0mcg. <\/p>\n<h3>O Fragmento 176-191 de HGH \u00e9 aprovado pela FDA?<\/h3>\n<p>No. HGH Fragment 176-191 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The related compound AOD9604 was investigated in clinical trials for obesity but did not achieve regulatory approval. <\/p>\n<h3>Como deve ser armazenado o HGH Fragment 176-191?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para estoque de trabalho de curto prazo, ou \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar dentro de 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congela\u00e7\u00e3o e descongela\u00e7\u00e3o degradam o p\u00e9ptido e podem perturbar a ponte dissulfeto essencial Cys182\u2013Cys189. Proteger da luz direta em todos os momentos. <\/p>\n<h3>Como reconstituir o HGH Fragment 176-191?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 2 a 5 minutos para dissolu\u00e7\u00e3o completa. N\u00e3o <strong>n\u00e3o<\/strong> Agitar o frasco \u2014 agita\u00e7\u00e3o vigorosa pode perturbar a liga\u00e7\u00e3o dissulfeto. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor. Para um frasco de 5 mg + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries HGH Fragment 176-191 in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Por que o HGH Fragment 176-191 n\u00e3o afeta o IGF-1?<\/h3>\n<p>The GH-receptor-binding surface of native human growth hormone is located in the N-terminal portion of the 191-amino-acid molecule, not in the C-terminal 176\u2013191 region. Because the fragment lacks the receptor-binding domain, it cannot activate the GH receptor; without GHR activation, the downstream JAK2\/STAT5 signalling cascade that drives hepatic IGF-1 transcription is not engaged. This structural-functional decoupling is the principal scientific reason the fragment retains studies interest as a lipolysis-isolating tool. <\/p>\n<h3>De onde vem a atividade lipol\u00edtica se n\u00e3o \u00e9 da liga\u00e7\u00e3o ao receptor GH?<\/h3>\n<p>The exact molecular target of HGH Fragment 176-191&#8217;s lipolytic action remains an active studies question. Proposed mechanisms include direct interaction with adipocyte beta-3 adrenergic receptors, modulation of hormone-sensitive lipase activity, and altered fatty-acid oxidation kinetics in adipose tissue. The fragment also suppresses lipogenic gene expression, suggesting it acts on multiple adipocyte-specific pathways simultaneously. Published studies continues to characterise the exact receptor or binding-site target. <\/p>\n<h3>Does HGH Fragment 176-191 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented a notably clean safety profile at typical doses, with the main on-target effect being lipolysis. The absence of GH-receptor binding means none of the GH-axis side effects observed with full-length HGH (transient insulin resistance, joint discomfort, sodium retention, mitogenic signalling) are present. Long-term human safety data is limited because the unmodified fragment has not undergone modern regulatory review (though the related AOD9604 has been investigated more extensively in clinical trials). <\/p>\n<h3>Qual \u00e9 a meia-vida do fragmento HGH 176-191?<\/h3>\n<p>In preclinical studies, HGH Fragment 176-191 has a plasma half-life of approximately 30 minutes following subcutaneous administration \u2014 shorter than full-length HGH (~3\u20135 hours) due to the smaller molecular size and absence of albumin-binding modifications. The short half-life means typical protocols use multiple daily administrations or continuous-release formulations for sustained-exposure work. <\/p>\n<h3>How long does HGH Fragment 176-191 take to show effects in preclinical studies?<\/h3>\n<p>Acute effects on adipocyte lipolysis and fatty-acid mobilisation are detectable within hours of administration. Body-composition effects in DIO rodent models typically become statistically significant after 2\u20134 weeks of regular dosing and continue to accrue through 8\u201312 weeks of continuous administration. The kinetics are similar to other adipose-tissue-targeted compounds. <\/p>\n<h3>Posso encomendar o fragmento HGH 176-191 para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia o fragmento HGH 176-191 para todo o mundo a partir da nossa rede dedicada de envio de pept\u00eddeos. As encomendas exclusivas de pept\u00eddeos qualificam-se para o nosso servi\u00e7o de envio de pept\u00eddeos aut\u00f3nomo. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Adipose, Growth-Axis, and Body-Composition Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Hormona de crescimento humana recombinante de comprimento total \u2014 a mol\u00e9cula-m\u00e3e deste fragmento<\/li>\n<li><a href=\"\/pt-pt\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adipose-tissue studies; FDA-approved for HIV-associated lipodystrophy<\/li>\n<li><a href=\"\/pt-pt\/cjc-1295-with-dac\/\"><strong>CJC-1295 com DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 endogenous GH-pulse support<\/li>\n<li><a href=\"\/pt-pt\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH(1-29) analog \u2014 short-acting GHRH use<\/li>\n<li><a href=\"\/pt-pt\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selective growth hormone secretagogue \u2014 clean GH pulse studies<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore the HGH-axis studies landscape<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com compostos relacionados do eixo de crescimento incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/hgh-191aa\/\">HGH 191AA<\/a> (forma parental completa), <a href=\"https:\/\/medsbase.com\/pt-pt\/tesamorelin\/\">Tesamorelin<\/a> (an\u00e1logo de GHRH da adiposidade visceral), <a href=\"https:\/\/medsbase.com\/pt-pt\/sermorelin\/\">Sermorelin<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/cjc-1295-with-dac\/\">CJC-1295 com DAC<\/a> for endogenous-pulse studies.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Fragmento C-terminal de 16-aa da hormona de crescimento humana<br \/>\n\u2705 Mant\u00e9m atividade lipol\u00edtica, sem liga\u00e7\u00e3o ao recetor de GH<br \/>\n\u2705 Sem indu\u00e7\u00e3o de IGF-1 ou efeitos promotores de crescimento<br \/>\n\u2705 Lipolysis-only tool (distinct from AOD9604)<br \/>\n\u2705 Pureza \u226599% por HPLC, COA dispon\u00edvel mediante pedido<\/p>\n<p><strong>Fragmento de HGH 176-191<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70959,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6288,6289,5441],"class_list":["post-70781","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-hgh","product_tag-hgh-fragment","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70781","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70781"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70959"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70781"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70781"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70781"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70781"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}